Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Insulin resistance and blood pressure.

Literature DB >> 18625163

Insulin resistance and blood pressure.

Sonya Addison¹, Sameer Stas, Melvin R Hayden, James R Sowers.

Abstract

Insulin resistance, cardiometabolic syndrome, and hypertension are common health problems with significant consequences for individuals and society. The pathogenesis of these disorders is complex and not fully understood. In this article we review the current knowledge about the effects of lifestyle modification and pharmacologic antihypertensive agents on insulin resistance and hypertension.

Entities: Disease Gene

Mesh：

Substances：

Year: 2008 PMID： 18625163 DOI： 10.1007/s11906-008-0059-1

Source DB: PubMed Journal: Curr Hypertens Rep ISSN： 1522-6417 Impact factor: 5.369

41 in total

Review 1. The metabolic syndrome and endothelial dysfunction: common highway to type 2 diabetes and CVD.

Authors: Michaela Diamant; Maarten E Tushuizen
Journal: Curr Diab Rep Date: 2006-08 Impact factor: 4.810

Review 2. Metabolic safety of antihypertensive drugs: myth versus reality.

Authors: Sameer Stas; Lama Appesh; James Sowers
Journal: Curr Hypertens Rep Date: 2006-10 Impact factor: 5.369

Review 3. Skeletal muscle insulin resistance is fundamental to the cardiometabolic syndrome.

Authors: Ravi Nistala; Craig S Stump
Journal: J Cardiometab Syndr Date: 2006

4. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage.

Authors: Anette Fiebeler; Jürg Nussberger; Erdenechimeg Shagdarsuren; Song Rong; Georg Hilfenhaus; Nidal Al-Saadi; Ralf Dechend; Maren Wellner; Silke Meiners; Christiane Maser-Gluth; Arco Y Jeng; Randy L Webb; Friedrich C Luft; Dominik N Muller
Journal: Circulation Date: 2005-06-06 Impact factor: 29.690

5. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors: Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal: N Engl J Med Date: 2003-03-31 Impact factor: 91.245

6. The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes.

Authors: Effie L Gillespie; C Michael White; Michael Kardas; Michael Lindberg; Craig I Coleman
Journal: Diabetes Care Date: 2005-09 Impact factor: 19.112

7. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors: Lars H Lindholm; Hans Ibsen; Björn Dahlöf; Richard B Devereux; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Stevo Julius; Sverre E Kjeldsen; Krister Kristiansson; Ole Lederballe-Pedersen; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel; Peter Aurup; Jonathan Edelman; Steven Snapinn
Journal: Lancet Date: 2002-03-23 Impact factor: 79.321

8. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190

9. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors: Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal: Lancet Date: 2004-06-19 Impact factor: 79.321

10. Aldosterone and hypertension in the cardiometabolic syndrome.

Authors: Sameer Stas; Adam T Whaley-Connell; James R Sowers
Journal: J Clin Hypertens (Greenwich) Date: 2008-02 Impact factor: 3.738

9 in total

1. The benefit of the Mediterranean-style diet in patients with newly diagnosed diabetes.

Authors: Efrain Reisin
Journal: Curr Hypertens Rep Date: 2010-04 Impact factor: 5.369

Review 2. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity.

Authors: Joseph Fomusi Ndisang
Journal: Mediators Inflamm Date: 2010-05-18 Impact factor: 4.711

3. Chronic Stress in Children and Adolescents: A Review of Biomarkers for Use in Pediatric Research.

Authors: Eileen M Condon
Journal: Biol Res Nurs Date: 2018-06-04 Impact factor: 2.522

4. Cocoa Consumption and Blood Pressure in Middle-Aged and Elderly Subjects: a Meta-Analysis.

Authors: Sadegh Jafarnejad; Mina Salek; Cain C T Clark
Journal: Curr Hypertens Rep Date: 2020-01-06 Impact factor: 5.369

5. S-allyl-mercapto-captopril: a novel compound in the treatment of Cohen-Rosenthal diabetic hypertensive rats.

Authors: Firas Younis; David Mirelman; Aharon Rabinkov; Talma Rosenthal
Journal: J Clin Hypertens (Greenwich) Date: 2010-06 Impact factor: 3.738

6. Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: a parallel, double-blind, controlled and randomised clinical trial.

Authors: Martine Paquette; Ana S Medina Larqué; S J Weisnagel; Yves Desjardins; Julie Marois; Geneviève Pilon; Stéphanie Dudonné; André Marette; Hélène Jacques
Journal: Br J Nutr Date: 2017-03-14 Impact factor: 3.718

Review 7. Insulin therapy and type 2 diabetes: management of weight gain.

Authors: Samy I McFarlane
Journal: J Clin Hypertens (Greenwich) Date: 2009-10 Impact factor: 3.738

Review 8. Effect of cocoa on blood pressure.

Authors: Karin Ried; Peter Fakler; Nigel P Stocks
Journal: Cochrane Database Syst Rev Date: 2017-04-25

9. The Hypertension of Hemophilia Is Not Explained by the Usual Cardiovascular Risk Factors: Results of a Cohort Study.

Authors: Richard F W Barnes; Thomas J Cramer; Afrah S Sait; Rebecca Kruse-Jarres; Doris V K Quon; Annette von Drygalski
Journal: Int J Hypertens Date: 2016-11-14 Impact factor: 2.420

9 in total